Share buy-back programme

RNS Number : 1038J
Bellevue Healthcare Trust PLC
22 April 2022
 

Bellevue Healthcare Trust plc (the "Company")

LEI: 213800HQ3J3H9YF2UI82

Share buy-back programme

Following the Company's AGM held earlier today, the Company announces that it has authority to repurchase a maximum of 86,904,879 of its ordinary shares (being its outstanding shareholder authority). Such authority lasts until the next shareholder authority granted, or where expressly revoked by shareholders. The buyback may be funded from the Company's resources (including redemptions on funds the Company has invested in and debt facilities). No maximum consideration payable has been determined by the Company, but the Company is unable to pay a price for any shares pursuant to the buy-back which would equate to a premium on the net asset value.

The Company has appointed J.P. Morgan Securities plc to act as its broker in respect of the buy-back. 

The buy-back will be undertaken pursuant the Company's discount management programme.

This arrangement is in accordance with Chapter 12 of the Listing Rules and the Company's general authority to repurchase shares.

Investors are reminded that, as per previous years, the company intends to offer shareholders the opportunity to redeem their shares at or near NAV at the end of the Company's financial year of 30 November 2022.

 

For further information please contact:

 

 Bellevue Asset Management (UK) Ltd.

 Mark Ghahramani

 Telephone: +44 (0) 203 326 2981

 

 J.P. Morgan Cazenove

 James Bouverat (Sales)

 Telephone: +44 (0) 207 134 2224

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSSEMFMEEESESL
UK 100

Latest directors dealings